Magnetic resonance imaging–guided laser interstitial thermal therapy as treatment for intractable insular epilepsy in children

M. Scott Perry, MD; David J. Donahue, MD; Saleem I. Malik, MD; Cynthia G. Keator, MD; Angel Hernandez, MD; Rohit K. Reddy, MD; Freedom F. Perkins Jr., MD; Mark R. Lee, MD, PhD; and Dave F. Clarke, MD

OBJECTIVE Seizure onset within the insula is increasingly recognized as a cause of intractable epilepsy. Surgery within the insula is difficult, with considerable risks, given the rich vascular supply and location near critical cortex. MRI-guided laser interstitial thermal therapy (LiTT) provides an attractive treatment option for insular epilepsy, allowing direct ablation of abnormal tissue while sparing nearby normal cortex. Herein, the authors describe their experience using this technique in a large cohort of children undergoing treatment of intractable localization-related epilepsy of insular onset.

METHODS The combined epilepsy surgery database of Cook Children’s Medical Center and Dell Children’s Hospital was queried for all cases of insular onset epilepsy treated with LiTT. Patients without at least 6 months of follow-up data and cases preoperatively designated as palliative were excluded. Patient demographics, presurgical evaluation, surgical plan, and outcome were collected from patient charts and described.

RESULTS Twenty patients (mean age 12.8 years, range 6.1–18.6 years) underwent a total of 24 LiTT procedures; 70% of these patients had normal findings on MRI. Patients underwent a mean follow-up of 20.4 months after their last surgery (range 7–39 months), with 10 (50%) in Engel Class I, 1 (5%) in Engel Class II, 5 (25%) in Engel Class III, and 4 (20%) in Engel Class IV at last follow-up. Patients were discharged within 24 hours of the procedure in 15 (63%) cases, in 48 hours in 6 (24%) cases, and in more than 48 hours in the remaining cases. Adverse functional effects were experienced following 7 (29%) of the procedures: mild hemiparesis after 6 procedures (all patients experienced complete resolution or had minimal residual dysfunction by 6 months), and expressive language dysfunction after 1 procedure (resolved by 3 months).

CONCLUSIONS To their knowledge, the authors present the largest cohort of pediatric patients undergoing insular surgery for treatment of intractable epilepsy. The patient outcomes suggest that LiTT can successfully treat intractable seizures originating within the insula and offers an attractive alternative to open resection. This is the first description of LiTT applied to insular epilepsy and represents one of only a few series describing the use of LiTT in children. The results indicate that seizure reduction after LiTT compares favorably to that after conventional open surgical techniques.

https://thejns.org/doi/abs/10.3171/2017.6.PEDS17158

KEY WORDS insular epilepsy; laser interstitial thermal therapy; epilepsy surgery

Intractable epilepsy with seizures originating in the insula and nearby perisylvian cortex is increasingly recognized, due in part to improved recognition of insular seizure semiology. Isnard et al. described the semiology and electroencephalography (EEG) features in patients with insular seizures, a stereotyped sequence of ictal symptoms including laryngeal constriction, paresthesia covering a large cutaneous territory, dysarthria, and focal motor convulsions. Data obtained from direct cortical stimulation of the insula supported the origin of these symptoms, and the authors concluded that the “sequence of ictal symptoms seemed reliable enough to characterize insular lobe epileptic seizures.” However, stereo-electroencephalography (SEEG) exploration in patients with focal
M. S. Perry et al.

Insular involvement has often revealed wider involvement in the epileptogenic zone, including frontal and central regions. Seizure semiology in these cases varied greatly, with an evolution from subtle seizures, spasms, and myoclonus to asymmetrical tonic and hypermotor events. Access to the insula is difficult and fraught with potential for collateral injury due to its deep location and rich vascular supply. The insula is nestled within the sylvian fissure between the frontotemporal opercula and basal ganglia. Its surface is draped by the M1 segments of the middle cerebral artery, bearing long and short perforators, some which also perfuse the corona radiata. The variety of proposed surgical approaches to invasive monitoring and resective epilepsy surgery within the insula attests to the trepidation (and dissatisfaction with available techniques) with which neurosurgeons approach the insula, especially in the dominant hemisphere. Its location and extensive connection with the rest of the brain often makes EEG evaluation challenging, with widespread or poorly localized onset using scalp EEG. In fact, insular onset has often been implicated as a reason behind failed epilepsy surgeries after frontal, temporal, or parietal lobe resection. With respect to insular resective surgery, some surgeons employ a transopercular corridor to avoid vasospasm at the sylvian fissure widely to allow either open freehand depth electrode placement or “pure” insular resection, apparently discounting the effects of dissection and retraction of opercular cortex and related blood vessels. In 1964, Silfvenius et al. reviewed the history of insular resection and noted the “considerably higher” rate of complications (20.6% vs 2.8%) when temporal lobectomy included insular resection. As a result, methods of surgical therapy for intractable insular epilepsy that avoid these potential dangers are worthwhile.

MRI-guided laser interstitial thermal therapy (LiTT) is a minimally invasive stereotactic surgical technique that can be employed to apply laser-induced heat to ablate epileptogenic foci. Application of LiTT for the surgical treatment of epilepsy has been largely restricted to lesional temporal lobe epilepsy, with limited data on morbidity and seizure outcome following extratemporal laser ablation. The minimally invasive nature of LiTT, along with its ability to provide real-time ablation monitoring and avoid collateral damage, suggests that thermal ablation has the potential to improve the surgical management of intractable insular epilepsy in appropriately selected candidates. We have used LiTT for the treatment of intractable pediatric epilepsy since 2013 and herein describe our experience with patients with insular epilepsy to date.

Methods

We queried our comprehensive epilepsy surgery database for all cases in which LiTT was performed within the insula. We excluded patients with less than 6 months of follow-up, those for whom follow-up was not available, and patients undergoing preoperatively designated palliative procedures. Baseline patient characteristics were collected, along with results of presurgical EEG and imaging evaluations. The study protocol was approved by the institutional review boards of both the Cook Children’s Medical Center and Dell Children’s Hospital with waiver of consent granted. All patients underwent preoperative 3-T, T1-weighted thin-slice (1-mm) MRI before and after administration of contrast. Video EEG data were available for all patients. Additional functional imaging, including SPECT, PET, and magnetoencephalography (MEG), was performed at the discretion of the treating epileptologist. Hemispheric language dominance was determined using either functional MRI (fMRI) or MEG with receptive and expressive language paradigms. If results of one modality were inconclusive of language localization, the alternative modality was completed. In cases in which neither fMRI nor MEG convincingly localized language dominance, Wada or cortical mapping using subdural grids was performed. Patient cases were reviewed, and surgical plans were formulated during a multidisciplinary epilepsy surgery conference of assembled epileptologists, neurosurgeons, neuroradiologists, and neuropsychologists. For patients without convincing localization based on preoperative noninvasive evaluation, extraparietal EEG monitoring was completed, incorporating either stereotactically placed depth electrodes or a combination of subdural grids and depth electrodes to better characterize the epileptogenic zone. Operative reports, along with intra- and postoperative MR images, documented the extent of insular ablation for each patient and were categorized as primarily anterior, posterior, or both. Postoperative clinic visit notes were reviewed to record outcome, which was defined according to Engel criteria. In cases in which initial ablation failed and the patient returned for a second procedure, outcome for the initial surgery was recorded as Engel Class IV for all time periods after the second surgery. Outcome is presented both for individual surgeries and for individual patients. For patients in whom initial LiTT failed, MRI was repeated and coregistered to prior preoperative imaging to evaluate completeness of ablation within the targeted epileptogenic zone. After review, patients returned for repeat LiTT procedures targeting the remaining epileptogenic zone.

Surgical Technique

For patients requiring invasive monitoring with depth electrodes, placement was performed using one of 2 techniques. For low lateral or multiple trajectories we prefer a technique employing robot assistance (ROSA, Medtech) similar to that described by González-Martínez et al. Stereotactic planning for insular coverage usually involved 2 electrode trajectories. One of these trajectories started in the occipital region and was designed to cover the entire length of either the posterior or anterior long gyrus (Fig. 1D, G, and I). Thus, the electrode trajectory passed through the insular cortex from posterior to anterior, deep to the middle cerebral vessels, and superior to the exter-
nal capsule. For the other trajectory, used in some cases, a frontal approach to the anterior insula from superior was employed, with the occipital approach targeting the posterior insula (Fig. 1A).

In some cases, subdural grid electrodes were used in addition to depth electrodes for monitoring the perisylvian cortex. In the same operative session, after placement of the depth electrodes, the Leksell frame was removed, and a Mayfield head holder was applied. The patient was positioned supine with a large shoulder roll, and the Mayfield head holder was attached to the operating table, with the vertex of the head neutral and the nasion slightly up. Typically, a large frontotemporal incision was made with the anterior fascia of the temporalis muscle brought with the skin flap dissection to protect the frontalis branch of the facial nerve. The temporalis muscle was incised at the anterior and posterior aspects of the exposure, and an osteoplastic bone flap was fashioned. The bone flap was retracted inferiorly, and the dura was opened. Electrocorticography was performed, and placement of the subdural grid electrodes was determined. Following closure of the dura and replacement of the bone flap, the electrode tails were tunneled out of separate stab wounds, and a JP drain was left in the subgaleal space. After recovering from anesthesia, patients were brought directly to the monitoring unit, and monitoring was started immediately. EEG monitoring continued until acquisition of adequate data was complete, patient data were again reviewed in a multidisciplinary con-

FIG. 1. Sagittal T1-weighted multiplanar reconstruction MR images obtained in 3 patients (1 patient per row) confirming laser fiber placement for the superior approach to the anterior insula (A), occipital approach to the posterior insula (D and I), and both approaches together (G). Postablation sagittal (B, E, and H), coronal (C), and axial (F) T2-weighted FLAIR images demonstrating region of thermal ablation in the anterior (B, C, and H) and posterior (E, F, and H) insulae.
ference, and surgical plans were discussed. Patients treated at Dell Children’s Comprehensive Epilepsy Program rou-
tinely immediately undergo LiTT following SEEG using
the same trajectory of the depth electrodes that define the
epileptogenic zone. Patients at Cook Children’s Medical
Center typically return 6–8 weeks after SEEG for LiTT
using similar trajectories modified in select cases to allow
for ablation of epileptogenic tissue characterized by mul-
tiple leads with a single laser fiber pass.

Surgical ablation of the insula was carried out using the
Visualase system (Medtronic) according to previously
described methods.4 An operative plan for the laser fiber
trajectory was fashioned using the same sequence for elec-
trode trajectory planning.

During the lesioning process, we employed the imag-
ing parameters and application of laser application as dis-
cussed elsewhere.4,17 For insular ablation, we generally use
the 3-mm diffuser tip catheter. Temperature safety limits
are entered to protect structures medial to the insula. Effec-
tive overnight and received perioperative doses of dexa-
methasone, which were tapered over 7–21 days.

T1-weighted postcontrast sequences. Patients were hospi-
talized overnight and received perioperative doses of dexa-
measone, which were tapered over 7–21 days.

Results

Patient Characteristics

Between January 2013 and September 2016, 26 patients
with intractable localization-related epilepsy underwent
31 LiTT procedures in which the insula was the surgical
target. Six patients (7 procedures) were excluded, 4 pa-
tients did not return for follow-up after surgery and lacked
follow-up data, and 2 were receiving palliative treatment.
The 20 remaining patients underwent 24 LiTT proc-
dures; 4 were repeat ablations after a failed initial abla-
tion procedure. The average age at surgery was 12.8 years
(range 6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-
ing an average of 2.2 antiepileptic drugs (AEDs) (range
6.1–18 years) with epilepsy onset at a mean age of
5.8 years (range 2 weeks–14 years). Patients were receiv-

Outcomes were evaluated for individual procedures. At
the 6-month follow-up (n = 24), patients in 10 cases
(42%) were in Engel Class I, those in 5 cases (21%) were
in Engel Class II (rare seizures), and those in 4 cases (17%) were
in Engel Class III.
<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age at Op (yrs)</th>
<th>Prior Op</th>
<th>Ictal VEEG</th>
<th>MRI</th>
<th>MEG</th>
<th>PET</th>
<th>SPECT</th>
<th>Invasive Monitoring</th>
<th>Ablation Target</th>
<th>FU Duration (mos)</th>
<th>Outcome Engel Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13.6</td>
<td>None</td>
<td>Bilat frontal</td>
<td>Lesion: tuber (rt frontal, lt frontal)</td>
<td>Rt frontal temp</td>
<td>NP</td>
<td>Rt frontal insular</td>
<td>SEEG</td>
<td>Rt frontal ant insula</td>
<td>32</td>
<td>IIa</td>
</tr>
<tr>
<td>2</td>
<td>15</td>
<td>Rt ant insula LITT</td>
<td>Rt frontal temp</td>
<td>Normal</td>
<td>Rt frontal</td>
<td>NP</td>
<td>NP</td>
<td>Grids/depths</td>
<td>Rt ant insula</td>
<td>20</td>
<td>IVb</td>
</tr>
<tr>
<td>3</td>
<td>18</td>
<td>Rt frontal disconnection</td>
<td>Rt frontal cent temp</td>
<td>Normal</td>
<td>Rt frontal</td>
<td>NP</td>
<td>Rt frontal temp</td>
<td>SEEG</td>
<td>Rt frontal ant insula</td>
<td>13</td>
<td>Ia</td>
</tr>
<tr>
<td>4</td>
<td>8</td>
<td>Lt ant insula LITT</td>
<td>Bilateral frontal</td>
<td>Lesion: lt insular CD</td>
<td>Bilateral frontal</td>
<td>NP</td>
<td>NP</td>
<td>Grids/depths</td>
<td>Lt ant insula</td>
<td>16</td>
<td>IVb</td>
</tr>
<tr>
<td>5</td>
<td>11.7</td>
<td>Rt frontal lobectomy</td>
<td>NP</td>
<td>Normal</td>
<td>Nonlocalizing</td>
<td>NP</td>
<td>NP</td>
<td>SEEG</td>
<td>Rt ant insula</td>
<td>13</td>
<td>IIIa</td>
</tr>
<tr>
<td>6</td>
<td>7.1</td>
<td>Lt pst temp &amp; pst insula</td>
<td>Lt cent temp</td>
<td>Normal</td>
<td>Lt frontal temp parietal</td>
<td>NP</td>
<td>Nonlocalizing</td>
<td>SEEG</td>
<td>Lt frontal pst insula</td>
<td>24</td>
<td>Ic</td>
</tr>
<tr>
<td>7</td>
<td>14.3</td>
<td>Lt frontal disconnection, lt insular resect</td>
<td>Nonlocalizing</td>
<td>Normal</td>
<td>Lt frontal</td>
<td>NP</td>
<td>Nonlocalizing</td>
<td>NP</td>
<td>Lt ant &amp; pst insula</td>
<td>25</td>
<td>IIIa</td>
</tr>
<tr>
<td>8</td>
<td>9.1</td>
<td>Rt frontal disconnection, rt ant insula resect</td>
<td>Rt frontal cent temp</td>
<td>Lesion: rt frontal insular CD</td>
<td>NP</td>
<td>NP</td>
<td>Rt frontal insular</td>
<td>Grids/depths</td>
<td>Rt frontal ant insula</td>
<td>39</td>
<td>Ia</td>
</tr>
<tr>
<td>9</td>
<td>12</td>
<td>None</td>
<td>Lt frontal temp</td>
<td>Normal</td>
<td>Lt frontal</td>
<td>NP</td>
<td>Lt frontal temp</td>
<td>SEEG</td>
<td>Lt pst insula</td>
<td>17</td>
<td>Ia</td>
</tr>
<tr>
<td>10</td>
<td>6.1</td>
<td>Lt ant insula LITT</td>
<td>Nonlocalizing</td>
<td>Normal</td>
<td>Lt insular</td>
<td>NP</td>
<td>Nonlocalizing</td>
<td>SEEG</td>
<td>Lt ant insula</td>
<td>14</td>
<td>Ia</td>
</tr>
<tr>
<td>11</td>
<td>16</td>
<td>None</td>
<td>NP</td>
<td>Normal</td>
<td>Bilateral frontal</td>
<td>NP</td>
<td>NP</td>
<td>SEEG</td>
<td>Rt frontal ant insula</td>
<td>15</td>
<td>IIb</td>
</tr>
<tr>
<td>12</td>
<td>17.6</td>
<td>Lt pst frontal resect</td>
<td>Lt frontal</td>
<td>Normal</td>
<td>Lt temp-parietal</td>
<td>NP</td>
<td>Lt ant insula</td>
<td>29</td>
<td>IIIc</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>10</td>
<td>None</td>
<td>Rt frontal temp</td>
<td>Lesion: rt insular tuber, rt frontal tuber</td>
<td>Rt frontal insular</td>
<td>NP</td>
<td>NP</td>
<td>NP</td>
<td>Rt frontal ant insula</td>
<td>25</td>
<td>Ia</td>
</tr>
<tr>
<td>14</td>
<td>9.4</td>
<td>Lt ant insula LITT</td>
<td>Lt insular</td>
<td>Normal</td>
<td>Bilateral temp</td>
<td>Nonlocalizing</td>
<td>Nonlocalizing</td>
<td>SEEG</td>
<td>Lt ant &amp; pst insula</td>
<td>13</td>
<td>IVb</td>
</tr>
<tr>
<td>15</td>
<td>18</td>
<td>None</td>
<td>Rt frontal</td>
<td>Normal</td>
<td>Rt insular</td>
<td>Rt temp insular</td>
<td>Nonlocalizing</td>
<td>SEEG</td>
<td>Lt pst insula</td>
<td>19</td>
<td>Ia</td>
</tr>
<tr>
<td>16</td>
<td>15.9</td>
<td>Lt parietal topectomy</td>
<td>Lt temp</td>
<td>Normal</td>
<td>Lt frontal</td>
<td>Nonlocalizing</td>
<td>Nonlocalizing</td>
<td>NP</td>
<td>Lt pst insula</td>
<td>25</td>
<td>Ia</td>
</tr>
<tr>
<td>17</td>
<td>13.1</td>
<td>Rt pst insular resect</td>
<td>Rt temp</td>
<td>Lesion: rt frontal insular CD</td>
<td>Rt insular</td>
<td>Rt frontal insular</td>
<td>Nonlocalizing</td>
<td>NP</td>
<td>Rt ant &amp; pst insula</td>
<td>35</td>
<td>Ia</td>
</tr>
<tr>
<td>18</td>
<td>17.9</td>
<td>Rt frontal opercular resect</td>
<td>Rt frontal temp</td>
<td>Lesion: bilateral frontal insular polymicrogyria</td>
<td>Rt frontal insular</td>
<td>Bilateral frontal insular</td>
<td>Nonlocalizing</td>
<td>NP</td>
<td>Rt frontal ant &amp; pst insula</td>
<td>18</td>
<td>IIIa</td>
</tr>
<tr>
<td>19</td>
<td>15.1</td>
<td>None</td>
<td>Bilateral frontal, rt frontal temp</td>
<td>Normal</td>
<td>Nonlocalizing</td>
<td>Nonlocalizing</td>
<td>SEEG</td>
<td>Rt ant &amp; pst insula</td>
<td>7*</td>
<td>IVb</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>17.0</td>
<td>Rt temp lobectomy</td>
<td>Rt frontal temp</td>
<td>Normal</td>
<td>Rt insular</td>
<td>Nonlocalizing</td>
<td>NP</td>
<td>SEEG</td>
<td>Rt ant insula</td>
<td>8</td>
<td>Ia</td>
</tr>
</tbody>
</table>

Ant = anterior; CD = cortical dysplasia; cent = central; FU = follow-up; NP = not performed; pst = posterior; resect = resection; temp = temporal; VEEG = video EEG.

* This patient was lost to follow-up at 7 months.
in Class III (worthwhile reduction). Patients in only 5 cases (21%) reported no improvement in seizure frequency (Engel Class IV). One-year data were available for 22 procedures; the patient in 1 case had not yet reached the 1-year postoperative time point, and another patient had not returned for follow-up. At 1 year, patients in 9 cases (41%) were seizure free, 1 (5%) patient reported only rare seizures (Engel Class II), those in 5 cases (22%) reported worthwhile reduction (Class III), and patients in 7 cases (32%) reported no significant improvement. Patients who underwent 10 total procedures had more than 2 years of follow-up; those who underwent 4 procedures (40%) remained seizure free, the patient in 1 case (10%) had only rare seizures, patients in 3 cases (30%) reported worthwhile improvement, and those in 2 cases (20%) reported no improvement. Patients were receiving 27% fewer AEDs following surgery and 4 had completely weaned off AEDs and remained seizure free.

Hospitalization and Adverse Events

Patients remained hospitalized an average of 1.8 days after surgery (range 1–10 days). Patients were discharged within 24 hours of the procedure in 15 (63%) cases, in 48 hours in 6 (24%) cases, and > 48 hours in the remaining cases. One patient remained hospitalized 10 days after the procedure because rehabilitation was needed for postoperative weakness. Only 1 patient was readmitted within 30 days of surgery because of hypertension and desaturation in sleep unrelated to surgery, which resolved within days. Adverse functional effects were experienced following 7 (29%) of the procedures. Of the 7 patients who underwent these procedures, 6 experienced mild hemiparesis (3 after anterior and 3 after posterior insular ablation, all completely resolved or were associated with minimal residual dysfunction by 6 months) and 1 experienced expressive language dysfunction (following anterior insular ablation, resolved by 3 months). Patients required nonnarcotic oral agents for pain control after 8 (30%) procedures and brief narcotic pain control without narcotics at discharge in 14 (58%) procedures. Only 3 (13%) patients required narcotic pain control after discharge.

Discussion

In this series, to our knowledge we present the largest cohort of pediatric patients undergoing insular surgery for the treatment of intractable epilepsy to date. While the number of insular surgeries over the 3-year study period was significant, this was largely due to increased recognition of insular epilepsy and an increased willingness to monitor and perform surgery in the insula using SEEG and LITT. Ten procedures were performed to reexamine previous surgeries that had failed, as insular onset is increasingly recognized as an etiology for failed temporal, frontal, or parietal resection. Our experience suggests that LITT can be used to successfully treat intractable epilepsy originating within the insula and offers an attractive alternative to open resection. To our knowledge, this is the first description of LITT applied to insular epilepsy and represents one of only a few series describing the use of LITT in children.

Our results indicate that seizure reduction after LITT compares favorably with conventional open surgical techniques. With an average follow-up of 20 months, 55% of our patients have experienced greater than 90% reduction in seizures following the procedure; 50% are seizure free 2 years postoperatively. While the number of patients with at least 2 years of follow-up is limited in our series (n = 8), those who were seizure free at 2 years have remained seizure free since surgery, and many have been weaned off medications, suggesting that favorable long-term outcome is possible with this technique. In a recent series of insular cortical resections in children published by Weil et al., 77% of patients had greater than 90% seizure reduction an average of 44 months after surgery. Likewise, Malak et al. described 7 patients (6 adults and 1 adolescent) who underwent insular resection (5 right sided and 2 left sided) for intractable epilepsy. Only one underwent “pure” insulectomy, while the others required varying degrees of associated opercular and/or temporal lobe resection. At follow-up ranging from 14 to 122 months, all but 1 patient achieved seizure freedom. While seizure freedom was more favorable in these patients, 3 (43%) sustained infarction within the corona radiata attributed to the surgery, and 4 (57%) of the 7 patients experienced transient postoperative hemiparesis, which resolved over months.

Gras-Combe et al. reported on 6 adult patients (of whom 4 had normal findings on MRI) undergoing right transpericranial insular resection after SEEG evaluation, of whom 5 at a mean follow-up of 36 months were rendered seizure free. All 6 of these patients were described as experiencing transient facial paresis or dysarthria. In our patients we did not note a difference in seizure-free outcome following pure insular ablation compared with ablation with opercular regions included. Only 7 (29%) of our patients experienced postoperative functional deficits following LITT with none persisting beyond 6 months, even when the opercular cortex was included in the target zone, suggesting that LITT offers an alternative to open resection with less morbidity. Likewise, we did not note a difference in the occurrence of postoperative deficits related to the region (i.e., anterior vs posterior) of the insula that was treated with ablation. Despite temperature control settings, structures lateral to the putamen, often including the extreme capsule, claustrum, and external capsule, appeared to have been injured as depicted on delayed follow-up imaging (Fig. 1C and F); however, adverse effects were minimal. Although longitudinal (as opposed to orthogonal) placement of the laser catheter would seem to achieve wider insular coverage and ablation, the curved and “uneven” nature of the lateral insular surface entails a relatively medial trajectory to avoid crossing multiple pial surfaces and associated subarachnoid spaces. As a result, some of our “insular ablations” may, in fact, represent “insular disconnections,” given the relationship of the laser fiber catheter just deep to the insular cortex. While seizure freedom may be less common after focused LITT procedures compared with open resection, the decreased risk of adverse effects with still significant likelihood of favorable outcome makes LITT an attractive consideration for initial surgical therapy.

LITT compares favorably with radiofrequency ablation, another minimally invasive approach to insular surgery.
Catenoix et al. described a series of 5 adult patients undergoing radiofrequency ablation of cortical malformations within the insula, which is “poorly accessible to surgical resection.” Although 4 patients were described as responding to treatment and 1 as seizure free, 2 stopped responding to treatment at 2 and 6 months. Thus, LiTT appears to offer more sustained seizure reduction in a larger proportion of patients, although the number of patients treated is too small to draw absolute conclusions.

This series is one of relatively few describing children undergoing LiTT for the treatment of epilepsy. Lewis et al. described their experience with 17 patients after LiTT for lesional intractable epilepsy. Forty-seven percent had a greater than 90% reduction in seizures at a mean of 16 months after therapy, similar to the outcomes presented in this series. The only other series of LiTT use in children, all with lesional epilepsy, consisted of 5 patients who underwent follow-up for 2–13 months after surgery. Our results are unique, not only because the insula was targeted for ablative treatment, but because 70% of our patients had normal findings on MRI. This suggests that LiTT can be used effectively in cases in which the findings are normal on MRI if the seizure onset zone is well delineated and of suitable size for ablation. Fifty-five percent of our patients with normal MRI findings were in Engel Class I or II postoperatively (mean follow-up 17.2 months, range 8–39 months).

In addition to comparing favorably with respect to seizure-free outcome and complications, LiTT requires shorter hospitalizations and thus would be expected to decrease the cost of care. Eighty-eight percent of our patients were discharged within 48 hours, and 63% were discharged within 1 day, similar to other series. Postoperative pain was minimal, as evidenced by only a few patients requiring narcotics. These factors enhance LiTT’s appeal to patients and their parents, compared with more invasive techniques. In addition, encouraging outcomes and likely reduced cost of care suggest that LiTT should be initially offered to appropriate candidates, with more invasive resective procedures considered if LiTT fails.

Despite our favorable outcomes using LiTT for insular epilepsy, 20% of our patients experienced no appreciable improvement after surgery. This is likely attributable to the difficulty localizing the epileptogenic network in these cases, more so than a failure of LiTT. Of the patients in whom treatment failed, most either underwent numerous nonlocalized presurgical functional imaging and neurophysiology studies or had multiple lesions (i.e., tuberous sclerosis) on MRI, suggesting widespread epileptogenic zones. While our SEEG investigations suggested that the insula was the primary node of onset, the procedures that failed suggest that the network and our monitoring of that network were insufficient to completely characterize and treat the onset zone. We continue revising our methods for monitoring the insula with SEEG such that we adequately include the insula but also the perisylvian cortex for complete characterization of the epileptogenic zone.

This initial series of LiTT use in intractable insular epilepsy provides encouraging data supporting the efficacy of this approach in achieving seizure freedom with minimal adverse effects. Our small cohort reflects the relative rarity of truly insular epilepsy. While our follow-up period is short, the seizure-free outcome for those with at least 1 year of follow-up appears significant and has been maintained for those with at least 2 years of follow-up. The fact that several patients have been weaned off of all medications strongly suggests that this approach is effective for some patients. Longer follow-up and increased numbers of patients undergoing LiTT for intractable epilepsy will help provide a definition of appropriate candidates for this therapy. At present, LiTT may be considered an option for patients with well-localized seizure onset when the seizure onset zone is amenable in size and location to ablative treatment.

Conclusions

While rare, the insula is increasingly recognized as a cause of intractable localization-related epilepsy. Excision within the insula carries considerable risks given the extensive blood supply and proximity to critical white matter tracts. This surgical technique results in seizure-free outcomes that are comparable to open resection and requires only brief hospital stays with limited postoperative pain. These factors make LiTT an attractive option for patients and families considering surgical treatment for insular epilepsy and should be considered in appropriate candidates.

References


Disclosures
The authors report the following. Dr. Donahue: consultant for Medtronic and Zimmer. Dr. Lee: consultant for Medtronic. Dr. Clarke: speakers’ bureau for Lundbeck Pharmaceuticals and grant money from the Anderson Foundation.

Author Contributions
Conception and design: Perry, Clarke. Acquisition of data: all authors. Analysis and interpretation of data: Perry. Clarke Drafting the article: Perry, Donahue, Lee, Clarke Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Perry. Administrative/technical/material support: Perry. Study supervision: Perry.

Supplemental Information
Previous Presentations
A portion of this work was previously presented in abstract form at the American Society for Stereotactic and Functional Neurosurgery meeting, Chicago, IL, June 18–21, 2016.

Correspondence
M. Scott Perry, Comprehensive Epilepsy Center, Cook Children’s Medical Center, 1500 Cooper St., 4th Fl., Fort Worth, TX 76104. email: scott.perry@cookchildrens.org.